Plain-English translation of NCT07008885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing —a new type of immune cell therapy where doctors remove your T cells (a type of white blood cell), modify them in the lab by removing two specific genes, and then infuse them back into your body. The goal is to help your immune system fight leukemia cells more effectively and for longer than standard CAR-T therapy currently does.
While standard CAR-T cell therapy has helped many patients with this type of leukemia, about 40–60% of people who respond initially relapse within a year because the modified cells don't persist long enough or become exhausted. This trial aims to improve the medication by making the cells stronger and longer-lasting.
You likely qualify if…
You likely don't qualify if…
You would first receive chemotherapy ( and ) to prepare your body. Then, doctors would collect your T cells through a procedure similar to dialysis, modify them in the laboratory by removing two genes, and infuse the modified cells back into you. You would be closely monitored with blood tests, scans, and clinical visits to assess how well the treatment works and watch for any side effects. The trial is testing different doses to find the safest and most effective amount.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China